Provided by Tiger Fintech (Singapore) Pte. Ltd.

Indaptus Therapeutics, Inc.

0.5000
+0.229985.12%
Pre-market: 0.4424-0.0576-11.52%04:19 EDT
Volume:365.36M
Turnover:211.98M
Market Cap:8.02M
PE:-0.34
High:0.7112
Open:0.5556
Low:0.4726
Close:0.2701
Loading ...

Indaptus Therapeutics Sells $2.3 Million of Convertible Notes, Warrants; Shares Fall Pre-Bell

MT Newswires Live
·
13 Jun

Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants

TIPRANKS
·
13 Jun

Indaptus Therapeutics Inc - Seeking to Raise up to $5 Mln in Gross Proceeds

THOMSON REUTERS
·
13 Jun

Indaptus Therapeutics Inc - Net Proceeds to Fund Phase 1B/2 Clinical Trial and Working Capital

THOMSON REUTERS
·
13 Jun

Indaptus Therapeutics Inc - Notes Bear Interest at 6% per Year, Maturing July 28, 2026

THOMSON REUTERS
·
13 Jun

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

THOMSON REUTERS
·
13 Jun

Indaptus Therapeutics Inc. Conducted Annual Meeting

Reuters
·
12 Jun

Indaptus Therapeutics Doses First Patient in Phase 1B/2 Combination Study of Decoy20 With Pd-1 Checkpoint Inhibitor Tislelizumab

THOMSON REUTERS
·
02 Jun

Indaptus Therapeutics Reports Q1 2025 Loss Per Share of $0.32, Improved from $0.45 in Q1 2024; R&D Expenses Rise to $2.8M

Reuters
·
14 May

Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients

MT Newswires Live
·
20 Mar

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

THOMSON REUTERS
·
20 Mar

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

GlobeNewswire
·
18 Mar

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

Benzinga
·
18 Mar

Indaptus Therapeutics FY24 EPS $(1.61) Up From $($1.83) YoY

Benzinga
·
13 Mar

BRIEF-Indaptus Therapeutics reports full-year loss of $1.61 per share

Reuters
·
13 Mar

Indaptus Therapeutics FY EPS USD -1.61

THOMSON REUTERS
·
13 Mar

Press Release: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Dow Jones
·
13 Mar

BRIEF-Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments

Reuters
·
04 Mar

Indaptus Therapeutics expands patent portfolio in China, Japan, Israel

TIPRANKS
·
04 Mar

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments

THOMSON REUTERS
·
04 Mar